التفاصيل البيبلوغرافية
| العنوان: |
Safety of alemtuzumab in a nationwide cohort of Finnish multiple sclerosis patients |
| المؤلفون: |
Rauma, I. (Ilkka), Mustonen, T. (Tiina), Seppä, J. M. (Juha Matti), Ukkonen, M. (Maritta), Männikkö, M. (Marianne), Verkkoniemi-Ahola, A. (Auli), Kartau, M. (Marge), Saarinen, J. T. (Jukka T.), Luostarinen, L. (Liisa), Simula, S. (Sakari), Ryytty, M. (Mervi), Ahmasalo, R. (Riitta), Sipilä, J. O. (Jussi O. T.), Pieninkeroinen, I. (Ilkka), Tapiola, T. (Tero), Remes, A. M. (Anne M.), Kuusisto, H. (Hanna) |
| بيانات النشر: |
Springer Nature |
| سنة النشر: |
2021 |
| المجموعة: |
Jultika - University of Oulu repository / Oulun yliopiston julkaisuarkisto |
| مصطلحات موضوعية: |
Alemtuzumab, Autoimmunity, Drug-related side effects and adverse reactions, Incidence, Multiple sclerosis, Safety |
| الوصف: |
Background: Alemtuzumab is an effective disease-modifying therapy (DMT) for highly active multiple sclerosis (MS). However, safety concerns limit its use in clinical practice. Objectives: To evaluate the safety of alemtuzumab in a nationwide cohort of Finnish MS patients. Methods: In this retrospective case series study, we analyzed the data of all but two MS patients who had received alemtuzumab in Finland until 2019. Data were systematically collected from patient files. Results: Altogether 121 patients were identified, most of whom had received previous DMTs (82.6%). Median follow-up time after treatment initiation was 30.3 months and exceeded 24 months in 78 patients. Infusion-associated reactions (IARs) were observed in 84.3%, 57.3%, and 57.1% of patients during alemtuzumab courses 1–3, respectively. Serious adverse events (SAEs) were observed in 32.2% of patients, serious IARs in 12.4% of patients, and SAEs other than IARs in 23.1% of patients. Autoimmune adverse events were observed in 30.6% of patients. One patient died of hemophagocytic lymphohistiocytosis, and one patient died of pneumonia. A previously unreported case of thrombotic thrombocytopenic purpura was documented. Conclusions: SAEs were more frequent in the present cohort than in previous studies. Even though alemtuzumab is a highly effective therapy for MS, vigorous monitoring with a long enough follow-up time is advised. |
| نوع الوثيقة: |
article in journal/newspaper |
| وصف الملف: |
application/pdf |
| اللغة: |
English |
| الإتاحة: |
http://urn.fi/urn:nbn:fi-fe2022031423406Test |
| حقوق: |
info:eu-repo/semantics/openAccess ; © The Author(s) 2021. This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0Test/. ; https://creativecommons.org/licenses/by/4.0Test/ |
| رقم الانضمام: |
edsbas.AD850163 |
| قاعدة البيانات: |
BASE |
